In this episode, our guest is Lewis Bender, Chairman, and CEO, of Intensity Therapeutics’ Founder which is a late-stage clinical biotechnology company whose mission is to help patients live longer, higher quality lives by discovering, developing, and commercializing first-in-class cancer drugs that attenuate tumors with minimal side effects, while training the patient’s immune system to fight the cancer. The Company’s lead product candidate, INT230-6, is currently in human clinical studies to treat refractory solid tumors.

Talking points:
Milestone Achievement: "Congratulations on dosing the first patient in the INVINCIBLE-4 Phase 2 clinical trial for triple-negative breast cancer. Can you walk us through the significance of this milestone and what it means for the future of Intensity Therapeutics?"

Innovative Approach of INT230-6: "Intensity Therapeutics focuses on developing cancer treatments that not only attenuate tumors with minimal side effects but also train the immune system to fight cancer. Could you explain how your lead product, INT230-6, achieves this unique approach and what differentiates it from existing cancer therapies?"

Collaboration with SAKK: "Your partnership with The Swiss Group for Clinical Cancer Research (SAKK) is a key component of the INVINCIBLE-4 study. How does this collaboration enhance your clinical development efforts, and what are you hoping to achieve together in this trial?"

Impact on Triple-Negative Breast Cancer (TNBC): "Triple-negative breast cancer is known for being particularly aggressive and having limited treatment options. How does INT230-6 address the unmet needs of TNBC patients, and what potential impact do you foresee it having on improving patient outcomes?"

Future Vision and Next Steps: "Looking ahead, what are the next steps for Intensity Therapeutics following the initiation of the INVINCIBLE-4 study? How do you envision the future of your company in the evolving landscape of cancer therapeutics?"

Guest - Lewis Bender

Host - Hillary Blackburn, PharmD, MBA

• https://www.linkedin.com/in/hillary-blackburn-67a92421/
• @talktoyourpharmacist for Instagram and Facebook

In this episode, our guest is Tom Campbell, the Dean and Associate Professor of Pharmacy Practice at Lipscomb University College of Pharmacy in Nashville. Dr. Campbell received his Pharm.D. degree from the University of Tennessee College of Pharmacy and received board certification in pharmacotherapy in 1995. His prior work experience includes a pharmacy practice residency with VA Medical Center in Memphis, Columbus Regional Health System in Columbus, Georgia, and Sanofi Pharmaceuticals. He also served as Clinical Assistant Professor at Auburn University. Dr. Campbell has served as President of the Tennessee Pharmacists Association and served on the Board of Directors. He is a member of AACP, ASHP, APhA, CPFI and TPA. He's a recipient of the 2024 APhA Academy of Student Pharmacists Outstanding Dean Award which was established to recognize a school or college of pharmacy dean who has made significant contributions to the APhA-ASP Chapter and promoted with distinction the welfare of student pharmacists through various community service, leadership and professional activities.

Dr. Campbell is a Sunday school teacher and former elder at the Spring Meadows Church of Christ in Spring Hill, TN. He has traveled to Central America as part of medical mission campaigns numerous times. Dr. Campbell and his late wife, Susan, have three sons.

During the discussion, we explored questions around:

• How faith influences our daily work in healthcare
• The ways faith impacts health behaviors and decision-making
• The role faith plays in job satisfaction and professional fulfillment

It was inspiring to engage in meaningful dialogue with a leader who also sees their work as a calling to serve others. I'm grateful to Dean Campbell at Lipscomb University for fostering conversations that remind us of the deeper purpose behind our careers.